Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial to find the best timing for radiotherapy and chemotherapy for advanced non small cell lung cancer (SOCCAR)
This trial looked at giving a course of radiotherapy and chemotherapy together, or one after the other, to see which might work best for non small cell lung cancer. This trial was supported by Cancer Research UK.
Some doctors thought that treatment may work better if patients had chemotherapy and radiotherapy at the same time (concurrently), rather than one after the other (sequentially). But this was a new way of treating NSCLC, and they were not sure how well it would work.
The aims of this trial were to collect information about the side effects of concurrent treatment and sequential treatment and to find out how well each treatment plan worked for non small cell lung cancer that could not be removed with surgery.
Summary of results
The trial team found that chemotherapy alongside 4 weeks of radiotherapy (concurrent treatment) is safe and can help people with non small cell lung cancer.
This trial was originally a phase 3 trial. But recruitment into the trial was slower than the researchers hoped. After talks with the steering committees, including the Independent Data Monitoring Committee (IDCM), it was decided to change SOCCAR to a phase 2 trial looking at the side effects of having concurrent treatment and how many people survived.
It was a randomised trial that recruited 130 people. They were put into 1 of 2 treatment groups. Neither they nor their doctor could choose which group they were in.
- 70 people had chemotherapy alongside radiotherapy (concurrent treatment)
- 60 people had chemotherapy then radiotherapy (sequential treatment)
The study started recruiting people in 2005, and they were followed up until January 2011. By the end of the trial, the number of people who were still alive was
- 26 out of the 70 people (37%) who had concurrent treatment
- 17 out of the 60 people (28%) who had sequential treatment
The overall average length of time people lived was
- Just over 2 years for those who had concurrent treatment
- About 1½ years for those who had sequential treatment
Overall there were fewer side effects and they were less severe in the concurrent treatment group than the sequential treatment group. The most common side effects reported in both groups were
- A drop in blood cells causing an increased risk of infection, bruising and bleeding
- Tiredness (fatigue)
- A change to the way the lungs work
- Feeling or being sick
- Inflammation of the food pipe (oesophagus)
- Numbness and tingling
The trial team concluded that having chemotherapy alongside 4 weeks of radiotherapy (concurrent treatment) could be safe and helpful for people who had non small cell lung cancer. They recommended that further research should be done to find out more about how helpful it could be.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Joe Maguire
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/04/006.